Similar articles

Abstract: COMPERA 2.0 risk stratification has been demonstrated to be useful in patients with precapillary pulmonary hypertension (PH). However, its suitability for patients at risk for post-capillary PH or PH associated with left heart disease (PH-LHD) is unclear. To investigate the use of COMPERA 2.0 in patients with severe aortic stenosis (SAS) undergoing transcatheter aortic valve replacement (TAVR), who are at risk for post-capillary PH, a total of 327 eligible SAS patients undergoing TAVR at our institution between September 2015 and November 2020 were included in the study. Patients were classified into four strata before and after TAVR using the COMPERA 2.0 risk score. The primary endpoint was all-cause mortality. Survival analysis was performed using Kaplan-Meier curves, log-rank test, and Cox proportional hazards regression model. The study cohort had a median (interquartile range) age of 76 (70‒80) years and a pulmonary arterial systolic pressure of 33 (27‒43) mmHg (1 mmHg=0.133 kPa) before TAVR. The overall mortality was 11.9% during 26 (15‒47) months of follow-up. Before TAVR, cumulative mortality was higher with an increase in the risk stratum level (log-rank, both P<0.001); each increase in the risk stratum level resulted in an increased risk of death (hazard ratio (HR) 2.53, 95% confidential interval (CI) 1.54‒4.18, P<0.001), which was independent of age, sex, estimated glomerular filtration rate (eGFR), hemoglobin, albumin, and valve type (HR 1.76, 95% CI 1.01‒3.07, P=0.047). Similar results were observed at 30 d after TAVR. COMPERA 2.0 can serve as a useful tool for risk stratification in patients with SAS undergoing TAVR, indicating its potential application in the management of PH-LHD. Further validation is needed in patients with confirmed post-capillary PH by right heart catheterization.

严重主动脉瓣狭窄患者的COMPERA 2.0风险分层：对左心疾病相关肺动脉高压的启示

[1]BermejoJ, YottiR, García-OrtaR, et al., 2018. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J, 39(15):1255-1264.

[2]BouclyA, WeatheraldJ, SavaleL, et al., 2022. External validation of a refined four-stratum risk assessment score from the french pulmonary hypertension registry. Eur Respir J, 59(6):2102419.

[3]GalièN, HumbertM, VachieryJL, et al., 2016. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J, 37(1):67-119.

[4]HadziselimovicE, GreveAM, SajadiehA, et al., 2022. Association of annual N-terminal pro-brain natriuretic peptide measurements with clinical events in patients with asymptomatic nonsevere aortic stenosis: a post hoc substudy of the seas trial. JAMA Cardiol, 7(4):435-444.

[5]HoeperMM, KramerT, PanZX, et al., 2017. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J, 50(2):1700740.

[6]HoeperMM, PauschC, OlssonKM, et al., 2022. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J, 60(1):2102311.

[7]HumbertM, KovacsG, HoeperMM, et al., 2022. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J, 43(38):3618-3731.

[8]HumbertM, KovacsG, HoeperMM, et al., 2023. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J, 61(1):2200879.

[9]MackMJ, LeonMB, SmithCR, et al., 2015. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, 385(9986):2477-2484.

[10]MaederMT, WeberL, RickliH, 2022. Pulmonary hypertension in aortic valve stenosis. Trends Cardiovasc Med, 32(2):73-81.

[11]MakkarRR, ThouraniVH, MackMJ, et al., 2020. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med, 382(9):799-809.

[12]MiyamotoJ, OhnoY, KamiokaN, et al., 2022. Impact of periprocedural pulmonary hypertension on outcomes after transcatheter aortic valve replacement. J Am Coll Cardiol, 80(17):1601-1613.

[13]O'LearyJM, ClavelMA, ChenS, et al., 2020. Association of natriuretic peptide levels after transcatheter aortic valve replacement with subsequent clinical outcomes. JAMA Cardiol, 5(10):1113-1123.

[14]O'SullivanCJ, WenaweserP, CeylanO, et al., 2015. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv, 8(7):e002358.

[15]OttoCM, NishimuraRA, BonowRO, et al., 2021. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation, 143(5):e72-e227.

[16]RadhoeSP, VeenisJF, van MieghemNM, et al., 2021. The effect of transcatheter aortic valve implantation on pulmonary artery pressures in a patient suffering from chronic heart failure: a case report. Eur Heart J-Case Rep, 5(4):ytab112.

[17]SatoK, KumarA, KrishnaswamyA, et al., 2019. B-type natriuretic peptide is associated with remodeling and exercise capacity after transcatheter aortic valve replacement for aortic stenosis. Clin Cardiol, 42(2):270-276.

[18]SchewelJ, SchmidtT, KuckKH, et al., 2019. Impact of pulmonary hypertension hemodynamic status on long-term outcome after transcatheter aortic valve replacement. JACC Cardiovasc Interv, 12(21):2155-2168.

[19]SigvardsenPE, LarsenLH, CarstensenHG, et al., 2017. Six-minute walking test and long term prognosis in patients with asymptomatic aortic valve stenosis. Int J Cardiol, 249:334-339.

[20]SimonneauG, MontaniD, CelermajerDS, et al., 2019. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J, 53(1):1801913.

[21]StubbsH, LuaS, BrewisM, et al., 2022. COMPERA 2.0 risk stratification in medically managed chronic thromboembolic pulmonary hypertension. Eur Respir J, 60(3):2200313.

[22]ThyregodHGH, IhlemannN, JorgensenTH, et al., 2019. Five-year clinical and echocardiographic outcomes from the NOTION randomized clinical trial in patients at lower surgical risk patients. Circulation, 139(24):2714-2723.

[23]TuttleMK, KiaiiB, van MieghemNM, et al., 2022. Functional status after transcatheter and surgical aortic valve replacement: 2-year analysis from the surtavi trial. JACC Cardiovasc Interv, 15(7):728-738.

[24]VachiéryJL, TedfordRJ, RosenkranzS, et al., 2019. Pulmonary hypertension due to left heart disease. Eur Respir J, 53(1):1801897.

[25]VahanianA, BeyersdorfF, PrazF, et al., 2022. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J, 43(7):561-632.

[26]Writing Committee Members, OttoCM, NishimuraRA, et al., 2021. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 77(4):e25-e197.

[27]XuHY, LiuQR, CaoK, et al., 2022. Distribution, characteristics, and management of older patients with valvular heart disease in China. JACC Asia, 2(3):354-365.